8 completed, 4 active not recruiting, 4 unknown, 3 recruiting. 7 Phase 2, 6 Phase 1, 5 Not applicable, 1 Phase 3.
Follow Urinary Bladder Neoplasm: new trials by email Literature Review of Urinary Bladder Neoplasm trials Research Report on Urinary Bladder Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors LY4052031, Pembrolizumab - Metastatic Solid Tumor, Recurrent Solid Tumor | Phase 1 | Recruiting | Eli Lilly and Company | 460 | 2024-07-01 | 2026-10-22 |
| A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors LY4101174 - Metastatic Solid Tumor, Recurrent Solid Tumor | Phase 1 | Active not recruiting | Eli Lilly and Company | 490 | 2024-03-05 | 2026-05-22 |
| Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab Nivolumab, Relatlimab - Urologic Neoplasms, Urogenital Neoplasms | Phase 2 | Active not recruiting | The Netherlands Cancer Institute | 90 | 2024-02-19 | 2026-07-15 |
| DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations Trastuzumab, Pertuzumab - Haematological Malignancy, Colorectal Neoplasms | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-07 | 2025-12-02 |
| SOX2 & PDL1 Expression on Urinary Bladder Carcinoma Urinary Bladder Neoplasm | Unknown | Sohag University | 60 | 2022-10-01 | 2022-06-23 | |
| Role of Diffusion -Weighted MRI in Evaluation of Urinary Bladder Masses MRI - Urinary Bladder Neoplasm | Unknown | Sohag University | 50 | 2021-11-01 | 2021-10-27 | |
| CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood Bipolar transurethral resection of bladder tumor (TURBT), Bipolar transurethral plasma kinetic vaporization of bladder tumor (PKVBT) - Urinary Bladder Neoplasm, Transitional Cell Carcinoma | Not applicable | Active not recruiting | University Teaching Hospital Hall in Tirol | 40 | 2021-03-14 | 2024-12-09 |
| Holmium Versus Bipolar en Bloc Transurethral Resection of Urothelium Tumor of the Urinary Bladder Holmium versus Bipolar en bloc transurethral resection - Urinary Bladder Neoplasm | Phase 2 | Completed | Ain Shams University | 100 | 2020-07-24 | 2025-01-28 |
| Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies BT8009, Pembrolizumab - Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms | Phase 1 / Phase 2 | Active not recruiting | BicycleTx Limited | 329 | 2020-07-17 | 2026-10-20 |
| Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy Fiducial marker placement, Multiparametric MRI (mpMRI) - Bladder Cancer, Urinary Bladder Neoplasm | Not applicable | Recruiting | Cedars-Sinai Medical Center | 60 | 2020-07-01 | 2025-08-14 |
| Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer Neutrophil to lymphocyte ratio - Urinary Bladder Cancer, Urinary Bladder Neoplasm | Completed | Ain Shams University | 96 | 2020-05-01 | 2023-07-18 | |
| The Importance of Muscle Function in Patients With Disseminated Bladder Cancer Evaluation of muscle mass and muscle function - Urinary Bladder Neoplasm | Unknown | Copenhagen University Hospital, Rigshospitalet | 30 | 2019-11-18 | 2019-11-20 | |
| Laser vs. Electorsurgical Enbloc Resection of Bladder Tumours Laser En Bloc Resection Of bladder Tumor, Electro-surgical En Bloc Resection Of bladder Tumor - Urinary Bladder Neoplasm | Not applicable | Unknown | Mansoura University | 100 | 2019-07-01 | 2019-07-26 |
| A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer Bempegaldesleukin, Nivolumab - Urinary Bladder Neoplasm, Neoplasm Metastasis | Phase 2 | Completed | Nektar Therapeutics | 192 | 2019-04-29 | 2023-03-28 |
| Evaluation of NanoDoce® in Participants With Urothelial Carcinoma NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care - Bladder Cancer, Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | NanOlogy, LLC | 36 | 2019-04-02 | 2023-08-14 |
| Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma autologous Tcm cells immunotherapy - Urinary Bladder Neoplasm | Phase 2 | Terminated | Beijing Huanxing Cancer Hospital | 6 | 2018-02-26 | 2021-12-01 |
| A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors SGN-2FF, pembrolizumab - Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell | Phase 1 | Terminated | Seagen Inc. | 47 | 2017-02-23 | 2019-07-19 |
| The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1), Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2) - Prostatic Neoplasm, Urinary Bladder Neoplasm | Not applicable | Completed | Seoul National University Hospital | 32 | 2016-11-01 | 2019-03-14 |
| Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery Fluid loading of volulyte 300 ml - Prostatic Neoplasm, Urinary Bladder Neoplasm | Not applicable | Completed | Seoul National University Hospital | 50 | 2016-11-01 | 2018-04-03 |
| Confocal Microscopy Dual Band in the Management of Bladder Cancer Cellvizio dual band - Urinary Bladder Neoplasm | Completed | Lille Catholic University | 3 | 2016-07-01 | 2018-10-31 |
Showing 20 of 21. Sign in to see all of them.
Urinary Bladder Neoplasms (21) · Neoplasms (5) · Prostatic Neoplasms (5) · Urologic Neoplasms (5) · Ovarian Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Transitional Cell (3) · Neoplasm Metastasis (3) · Pancreatic Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Triple Negative Breast Neoplasms (3) · Urogenital Neoplasms (3) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Esophageal Neoplasms (2)
Urologic Diseases (21) · Female Urogenital Diseases (20) · Female Urogenital Diseases and Pregnancy Complications (20) · Male Urogenital Diseases (20) · Neoplasms by Site (20) · Urogenital Diseases (20) · Urinary Bladder Diseases (19) · Urogenital Neoplasms (18) · Neoplasms (16) · Urologic Neoplasms (16) · Carcinoma (6) · Genital Diseases (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Pathological Conditions, Signs and Symptoms (6)
pembrolizumab (3) · Nivolumab (2) · Administration, Intravesical (1) · Docetaxel (1) · Mitomycin (1) · Multiparametric Magnetic Resonance Imaging (1) · Neoadjuvant Therapy (1) · Trastuzumab (1) · bempegaldesleukin (1) · pertuzumab (1) · relatlimab (1)
Ain Shams University (2) · Eli Lilly and Company (2) · Seoul National University Hospital (2) · Sohag University (2) · Beijing Huanxing Cancer Hospital (1) · BicycleTx Limited (1) · Cancer Research UK (1) · Cedars-Sinai Medical Center (1) · Copenhagen University Hospital, Rigshospitalet (1) · Lille Catholic University (1) · Mansoura University (1) · NanOlogy, LLC (1) · Nektar Therapeutics (1) · Seagen Inc. (1) · The Netherlands Cancer Institute (1)
United States (8) · France (5) · Egypt (4) · Spain (4) · United Kingdom (4) · Australia (3) · China (3) · South Korea (3) · Belgium (2) · Canada (2) · Italy (2) · Japan (2) · Netherlands (2) · Argentina (1) · Austria (1)
Ahmed Elshal, MD (1) · Christina Derleth, MD (1) · Donald Lamm, MD, FACS (1) · Dong Wang, Master (1) · Jean-Louis Bonnal, MD (1) · Linjun Hu (1) · Lise Hoej Omland, MD (1) · Lukas Lusuardi, MD, Prof. (1) · Matthew Krebs, Dr (1) · Maurice Garcia, MD (1) · Meredith McKean, MD, MPH (1) · Michiel Van der Heijden, PhD (1) · Robert S. Svatek, MD, MSCI (1)
2018 (1), 2023 (1), R01CA201709 (1)